The Medsintez plant is an innovative pharmaceutical enterprise that manufactures vital and major medicines. Today, the plant's developments are focused on the area, which is among the most demanded ones by the Russian healthcare system, namely creating drugs for diabetes. Read on to find out how the company operates on the modern biotech market.
Pharmacists are able to fully meet the demand in the regional market Industrial manufacturing of drugs in the Sverdlovsk region has a 90-year history. JSC “Uralbiopharm” was founded in 1930 and today it continues to occupy a strong position in the pharmaceutical industry of Russia. In 1942 the chemical and pharmaceutical plant was built in Irbit, one of the few production facilities in Russia that has its own chemical synthesis of pharmaceutical substances. The pharmaceutical industry boom occurred in 2000s when modern enterprises such as OAO “Zavod Medsintez” in Novouralsk and Lekas plant in Beryozovsky town that produces products complying with international GMP standards appeared in the region. Enterprises of the Sverdlovsk region produce a wide range of drugs many of which are much sought after among citizens. They have set up their own production of medicines included in the state register of vital and essential medicines. In most cases, medicines produced by the Ural manufacturers have a similar effect with proven effectiveness as their foreign analogues but cost less.
The coronavirus pandemic has become a serious test for thousands of Russian enterprises. Some of them failed to adapt to the new reality and dropped out of the game. Others have become the vanguard in the fight against COVID-19 and its consequences. Medsintez, a pharmaceutical plant, is in their number. In 2020, it assumed an extra responsibility for the quality and duration of life of Russia citizens.
The government commission for more sustainable development of the Russian economy, according to its meeting's minutes No. 13-КЗ of June 19, 2020, included the Medsintez plant into the list of the Russian Federation's systemic enterprises whose products or services are vital for sustaining a territory, functioning of an industry and a region's social and economic system.
In June 2020, the Medsintez plant entered an agreement to join the Bioorganika Consortium of the Center for the National Technological Initiative of the Federal State Budgetary Institution 'Institute of Bioorganic Chemistry named after Academicians M. M. Shemyakin and Yu. A. Ovchinnikov' of the Russian Academy of Sciences (IBCh RAS).